intellia therapeutics

Intellia, Morgan Stanley

Intellia Therapeutics (NASDAQ:NTLA) Stock Rating Lowered by Morgan Stanley

Morgan Stanley lowered shares of Intellia Therapeutics (NASDAQ:NTLA – Free Report) from an overweight rating to an equal weight rating in a report published on Monday morning, MarketBeat.com reports.

Investing.com on MSN · 3d

Morgan Stanley cuts Intellia stock rating amid gene editing concerns

Morgan Stanley (NYSE:MS) adjusted its stance on Intellia Therapeutics shares, downgrading the biotechnology company from Overweight to Equalweight. Accompanying this change, the firm also significantly reduced its price target to $11.

Seeking Alpha · 3d

Intellia downgraded at Morgan Stanley on lowered expectations for rare disease asset

Morgan Stanley has downgraded Intellia Therapeutics (NASDAQ:NTLA) to equal weight from overweight citing "a more measured launch" of its transthyretin amyloidosis (ATTR) candidate nexiguran ...

Business Insider · 3d

Intellia Therapeutics downgraded to Equal Weight from Overweight at Morgan Stanley

Morgan Stanley downgraded Intellia Therapeutics (NTLA) to Equal Weight from Overweight with a price target of $11, down from $56. The firm now

Hosted on MSN13d

Intellia Loses 21.6% in a Week: How Should You Play the Stock?

Intellia Therapeutics, Inc. NTLA lost 21.6% in a week as investors were disappointed with the company’s plans for portfolio ...

13d

Editas And Intellia: Strategic Shifts And Long-Term Investment Potential

A look at Intellia Therapeutics, Inc. and Editas Medicine, Inc., including their restructuring and pipeline prioritization.

Morningstar2d

Intellia Therapeutics Inc NTLA

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Bronstein, Gewirtz & Grossman, LLC Encourages Intellia Therapeutics, Inc. (NTLA) Shareholders to Inquire about Securities Investigation

NEW YORK CITY, NY / ACCESS Newswire / January 26, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims ...

18d

BMO Capital Markets Issues Pessimistic Forecast for Intellia Therapeutics (NASDAQ:NTLA) Stock Price

Intellia Therapeutics (NASDAQ:NTLA – Get Free Report) had its price target dropped by equities research analysts at BMO Capital Markets from $70.00 to $50.00 in a research report issued to clients and ...

precisionmedicineonline8d

Intellia Therapeutics Doses First Patient in Phase III Hereditary Angioedema Trial of CRISPR Drug

The company expects to submit a biologics license application for NTLA-2002 in 2026 and potentially launch it in the US in 2027.

Some results have been hidden because they may be inaccessible to you

Show inaccessible results